Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01315171 · ClinicalTrials.gov registry record · NA

Effect of a Medium Chain Triglyceride Supplemented Diet on Cognitive Function and Brain Activation in Type 1 Diabetes.

A NA study, sponsored by Yale University.

Completed
Registry status
NA
Development phase
12
Enrollment target

NCT01315171 is a NA study that has completed, run by Yale University. The registered enrollment target is 12 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01315171, a NA study, has completed, sponsored by Yale University.

COMPLETED
Registry status
NA
Development phase
12 participants
Enrollment target

Study Summary

Insulin treatment often causes the blood glucose levels to fall too low (hypoglycemia). Hypoglycemia can be associated with confusion and disorientation as well as other symptoms such as palpitations, sweating and tremors. Medium chain triglycerides (MCT) can be used as a fuel in the brain during low blood sugar levels and therefore may prevent or reduce some of the confusion and disorientation seen during hypoglycemia. We would like to determine if a diet supplemented with medium chain triglycerides can improve cognitive function during hypoglycemia, diabetes control and also look at brain activity.

Interventions

  • DIETARY_SUPPLEMENT Medium chain triglycerides

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2012-01
Est. Completion 2016-10
Phase NA

Sponsor

Yale University

1,492 total trials

What the Registry Record Tells You About NCT01315171

The ClinicalTrials.gov registry entry for NCT01315171 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Medium chain triglycerides is the first listed.

NCT01315171 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01315171 about?

NCT01315171 is a clinical study titled "Effect of a Medium Chain Triglyceride Supplemented Diet on Cognitive Function and Brain Activation in Type 1 Diabetes.". Insulin treatment often causes the blood glucose levels to fall too low (hypoglycemia). Hypoglycemia can be associated with confusion and disorientation as well as other symptoms such as palpitations, sweating and tremors. Medium chain triglycerides (MCT) can be used as a fuel in the brain during lo...

What is the current status of trial NCT01315171?

This trial is currently completed. It is a NA study. The enrollment target is 12 participants. The study started on 2012-01. Estimated completion is 2016-10.

What interventions are being tested in trial NCT01315171?

The interventions under investigation include: Medium chain triglycerides (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT01315171?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.